




PHARMACEUTICAL 2021

Aeglea BioTherapeutics Inc.
Rank 123 of 402





PHARMACEUTICAL 2021

Aeglea BioTherapeutics Inc.
Rank 123 of 402



The relative strengths and weaknesses of Aeglea BioTherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aeglea BioTherapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Aeglea BioTherapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 31% points.

The company's Economic Capital Ratio, given in the ranking table, is 174%, being 127% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	149,789
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,443
Liabilities, Non-Current	5,343
Other Assets	6,187
Other Compr. Net Income	-40
Other Expenses	0
Other Liabilities	0
Other Net Income	588
Other Revenues	0
Property and Equipment	5,642
Research and Development	59,638
Selling, General and Administrative Expense	21,843

Output Variable	Value in 1000 USD
Assets	161,618
Liabilities	21,786
Expenses	81,481
Revenues	0
Stockholders Equity	139,832
Net Income	-80,893
Comprehensive Net Income	-80,913
Economic Capital Ratio	174%